Induction of chromosomal instability via telomere dysfunction and epigenetic alterations in myeloid neoplasia

Cancers

Volumn 5, Issue 3, 2013, Pages 857-874

  Vajen, Beate ^a   Thomay, Kathrin ^a   Schlegelberger, Brigitte ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

AML; Chromosomal instability; Epigenetics; Genetic instability; MDS; Myeloid leukemia; Telomeres

Indexed keywords

DNA METHYLTRANSFERASE 3A; TRANSCRIPTION FACTOR EZH2;

ACUTE GRANULOCYTIC LEUKEMIA; ASXL1 GENE; BONE MARROW TUMOR; CARCINOGENESIS; CHROMOSOMAL INSTABILITY; CHROMOSOME ABERRATION; CHROMOSOME DISORDER; CHROMOSOME REARRANGEMENT; CLONAL EVOLUTION; DISEASE COURSE; DNMT3A GENE; EPIGENETICS; EZH2 GENE; GENE MUTATION; GENETIC REGULATION; GENOMIC INSTABILITY; HISTONE METHYLATION; HUMAN; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; KARYOTYPE; LEUKEMOGENESIS; MYELODYSPLASTIC SYNDROME; NONHUMAN; REGULATOR GENE; REVIEW; TELOMERE SHORTENING; TET2 GENE; TUMOR GENE;

EID: 84880112197     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers5030857     Document Type: Review

References (90)

1. Cahill, D.P.; Kinzler, K.W.; Vogelstein, B.; Lengauer, C. Genetic instability and Darwinian selection in tumours. Trends Cell. Biol. 1999, 9, M57-M60.
2. Nowak, M.A.; Komarova, N.L.; Sengupta, A.; Jallepalli, P.V.; Shih Ie, M.; Vogelstein, B.; Lengauer, C. The role of chromosomal instability in tumor initiation. Proc. Natl. Acad. Sci. USA 2002, 99, 16226-16231.
3. Lengauer, C.; Kinzler, K.W.; Vogelstein, B. Genetic instabilities in human cancers. Nature 1998, 396, 643-649.
4. Geigl, J.B.; Obenauf, A.C.; Schwarzbraun, T.; Speicher, M.R. Defining -"chromosomal instability". Trends Genet. 2008, 24, 64-69.
5. Janssen, A.; Medema, R.H. Genetic instability: Tipping the balance. Oncogene 2012, doi:10.1038/onc.2012.576.
6. Bayani, J.; Selvarajah, S.; Maire, G.; Vukovic, B.; Al-Romaih, K.; Zielenska, M.; Squire, J.A. Genomic mechanisms and measurement of structural and numerical instability in cancer cells. Semin. Cancer Biol. 2007, 17, 5-18.
7. McGranahan, N.; Burrell, R.A.; Endesfelder, D.; Novelli, M.R.; Swanton, C. Cancer chromosomal instability: Therapeutic and diagnostic challenges. EMBO Rep. 2012, 13, 528-538.
8. Wilkens, L.; Flemming, P.; Gebel, M.; Bleck, J.; Terkamp, C.; Wingen, L.; Kreipe, H.; Schlegelberger, B. Induction of aneuploidy by increasing chromosomal instability during dedifferentiation of hepatocellular carcinoma. Proc. Natl. Acad. Sci. USA 2004, 101, 1309-1314.
9. Heilig, C.E.; Loffler, H.; Mahlknecht, U.; Janssen, J.W.; Ho, A.D.; Jauch, A.; Kramer, A. Chromosomal instability correlates with poor outcome in patients with myelodysplastic syndromes irrespectively of the cytogenetic risk group. J. Cell Mol. Med. 2010, 14, 895-902.
10. Greenberg, P.L.; Tuechler, H.; Schanz, J.; Sanz, G.; Garcia-Manero, G.; Sole, F.; Bennett, J.M.; Bowen, D.; Fenaux, P.; Dreyfus, F., et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood 2012, 120, 2454-2465.
11. Jadersten, M.; Hellstrom-Lindberg, E. New clues to the molecular pathogenesis of myelodysplastic syndromes. Exp. Cell. Res. 2010, 316, 1390-1396.
12. Swerdlow, S.; Campo, E.; Harris, N.; Jaffe, E.; Pileri, S.; Stein, H.; Thiele, J.; Vardiman, J. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th ed.; IARC: Lyon, France, 2008.
13. Malcovati, L.; Germing, U.; Kuendgen, A.; Della Porta, M.G.; Pascutto, C.; Invernizzi, R.; Giagounidis, A.; Hildebrandt, B.; Bernasconi, P.; Knipp, S., et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J. Clin. Oncol. 2007, 25, 3503-3510.
14. Germing, U.; Strupp, C.; Giagounidis, A. Clinical features and prognosis of patients with myelodysplastic syndromes. Cancer Treat. Rev. 2007, 33, S15-S18.
15. Gohring, G.; Michalova, K.; Beverloo, H.B.; Betts, D.; Harbott, J.; Haas, O.A.; Kerndrup, G.; Sainati, L.; Bergstraesser, E.; Hasle, H., et al. Complex karyotype newly defined: The strongest prognostic factor in advanced childhood myelodysplastic syndrome. Blood 2010, 116, 3766-3769.
16. Haase, D.; Germing, U.; Schanz, J.; Pfeilstocker, M.; Nosslinger, T.; Hildebrandt, B.; Kundgen, A.; Lubbert, M.; Kunzmann, R.; Giagounidis, A.A., et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: Evidence from a core dataset of 2124 patients. Blood 2007, 110, 4385-4395.
17. Pedersen-Bjergaard, J.; Andersen, M.T.; Andersen, M.K. Genetic pathways in the pathogenesis of therapy-related myelodysplasia and acute myeloid leukemia. Hematology Am. Soc. Hematol. Educ. Program 2007, 1, 392-397.
18. Corey, S.J.; Minden, M.D.; Barber, D.L.; Kantarjian, H.; Wang, J.C.; Schimmer, A.D. Myelodysplastic syndromes: The complexity of stem-cell diseases. Nat. Rev. Cancer 2007, 7, 118-129.
19. Huret, J.; Chomienne, C. t(15;17)(q24;q21). Available online: http://atlasgeneticsoncology.org/Anomalies/t1517ID1035.html/ (accessed on 17 June 2013).
20. Dohner, H.; Estey, E.H.; Amadori, S.; Appelbaum, F.R.; Buchner, T.; Burnett, A.K.; Dombret, H.; Fenaux, P.; Grimwade, D.; Larson, R.A., et al. Diagnosis and management of acute myeloid leukemia in adults: Recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010, 115, 453-474.
21. Lugthart, S.; Groschel, S.; Beverloo, H.B.; Kayser, S.; Valk, P.J.; van Zelderen-Bhola, S.L.; Jan Ossenkoppele, G.; Vellenga, E.; van den Berg-de Ruiter, E.; Schanz, U., et al. Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia. J. Clin. Oncol. 2010, 28, 3890-3898.
22. Dohner, H.; Gaidzik, V.I. Impact of genetic features on treatment decisions in AML. Hematology Am. Soc. Hematol. Educ. Program 2011, 2011, 36-42.
23. Bejar, R.; Stevenson, K.; Abdel-Wahab, O.; Galili, N.; Nilsson, B.; Garcia-Manero, G.; Kantarjian, H.; Raza, A.; Levine, R.L.; Neuberg, D., et al. Clinical effect of point mutations in myelodysplastic syndromes. N. Engl. J. Med. 2011, 364, 2496-2506.
24. Swiggers, S.J.; Kuijpers, M.A.; de Cort, M.J.; Beverloo, H.B.; Zijlmans, J.M. Critically short telomeres in acute myeloid leukemia with loss or gain of parts of chromosomes. Genes Chromosomes Cancer 2006, 45, 247-256.
25. Sieglova, Z.; Zilovcova, S.; Cermak, J.; Rihova, H.; Brezinova, D.; Dvorakova, R.; Markova, M.; Maaloufova, J.; Sajdova, J.; Brezinova, J., et al. Dynamics of telomere erosion and its association with genome instability in myelodysplastic syndromes (MDS) and acute myelogenous leukemia arising from MDS: A marker of disease prognosis? Leuk. Res. 2004, 28, 1013-1021.
26. Boultwood, J.; Fidler, C.; Kusec, R.; Rack, K.; Elliott, P.J.; Atoyebi, O.; Chapman, R.; Oscier, D.G.; Wainscoat, J.S. Telomere length in myelodysplastic syndromes. Am. J. Hematol. 1997, 56, 266-271.
27. Blasco, M.A.; Lee, H.W.; Hande, M.P.; Samper, E.; Lansdorp, P.M.; DePinho, R.A.; Greider, C.W. Telomere shortening and tumor formation by mouse cells lacking telomerase RNA. Cell 1997, 91, 25-34.
28. Hemann, M.T.; Rudolph, K.L.; Strong, M.A.; DePinho, R.A.; Chin, L.; Greider, C.W. Telomere dysfunction triggers developmentally regulated germ cell apoptosis. Mol. Biol. Cell 2001, 12, 2023-2030.
29. Shay, J.W.; Wright, W.E. Senescence and immortalization: Role of telomeres and telomerase. Carcinogenesis 2005, 26, 867-874.
30. Bullinger, L.; Dohner, K.; Bair, E.; Frohling, S.; Schlenk, R.F.; Tibshirani, R.; Dohner, H.; Pollack, J.R. Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. N. Engl. J. Med. 2004, 350, 1605-1616.
31. Alvarez, S.; Suela, J.; Valencia, A.; Fernandez, A.; Wunderlich, M.; Agirre, X.; Prosper, F.; Martin-Subero, J.I.; Maiques, A.; Acquadro, F., et al. DNA methylation profiles and their relationship with cytogenetic status in adult acute myeloid leukemia. PLoS One 2010, 5, e12197.
32. Bullinger, L.; Ehrich, M.; Dohner, K.; Schlenk, R.F.; Dohner, H.; Nelson, M.R.; van den Boom, D. Quantitative DNA methylation predicts survival in adult acute myeloid leukemia. Blood 2010, 115, 636-642.
33. Nolte, F.; Giehl, M.; Haass, W.; Nowak, V.; Schumann, C.; Nowak, D.; Mossner, M.; Popp, H.D.; Schulze, T.J.; Klein, S., et al. Centrosome aberrations in bone marrow cells from patients with myelodysplastic syndromes correlate with chromosomal instability. Ann. Hematol. 2013, doi:10.1007/s00277-013-1772-7.
34. Burrell, R.A.; McClelland, S.E.; Endesfelder, D.; Groth, P.; Weller, M.C.; Shaikh, N.; Domingo, E.; Kanu, N.; Dewhurst, S.M.; Gronroos, E., et al. Replication stress links structural and numerical cancer chromosomal instability. Nature 2013, 494, 492-496.
35. Rassool, F.V.; Gaymes, T.J.; Omidvar, N.; Brady, N.; Beurlet, S.; Pla, M.; Reboul, M.; Lea, N.; Chomienne, C.; Thomas, N.S., et al. Reactive oxygen species, DNA damage, and error-prone repair: A model for genomic instability with progression in myeloid leukemia? Cancer. Res. 2007, 67, 8762-8771.
36. Sallmyr, A.; Tomkinson, A.E.; Rassool, F.V. Up-regulation of WRN and DNA ligase IIIalpha in chronic myeloid leukemia: Consequences for the repair of DNA double-strand breaks. Blood 2008, 112, 1413-1423.
37. Popp, H.D.; Bohlander, S.K. Genetic instability in inherited and sporadic leukemias. Genes Chromosomes Cancer 2010, 49, 1071-1081.
38. Drummond, M.W.; Balabanov, S.; Holyoake, T.L.; Brummendorf, T.H. Concise review: Telomere biology in normal and leukemic hematopoietic stem cells. Stem Cells 2007, 25, 1853-1861.
39. Hayflick, L. The limited in vitro lifetime of human diploid cell strains. Exp. Cell Res. 1965, 37, 614-636.
40. Hemann, M.T.; Strong, M.A.; Hao, L.Y.; Greider, C.W. The shortest telomere, not average telomere length, is critical for cell viability and chromosome stability. Cell 2001, 107, 67-77.
41. Calado, R.T.; Regal, J.A.; Hills, M.; Yewdell, W.T.; Dalmazzo, L.F.; Zago, M.A.; Lansdorp, P.M.; Hogge, D.; Chanock, S.J.; Estey, E.H., et al. Constitutional hypomorphic telomerase mutations in patients with acute myeloid leukemia. Proc. Natl. Acad. Sci. USA 2009, 106, 1187-1192.
42. Shay, J.W.; Wright, W.E. Telomeres and telomerase in normal and cancer stem cells. FEBS Lett. 2010, 584, 3819-3825.
43. Martinez, P.; Blasco, M.A. Telomeric and extra-telomeric roles for telomerase and the telomere-binding proteins. Nat. Rev. Cancer 2011, 11, 161-176.
44. Blackburn, E.H.; Collins, K. Telomerase: An RNP enzyme synthesizes DNA. Cold Spring Harb. Perspect. Biol. 2011, doi:10.1101/chsperspect.a003558.
45. Artandi, S.E. Telomeres, telomerase, and human disease. N. Engl. J. Med. 2006, 355, 1195-1197.
46. Drummond, M.W.; Hoare, S.F.; Monaghan, A.; Graham, S.M.; Alcorn, M.J.; Keith, W.N.; Holyoake, T.L. Dysregulated expression of the major telomerase components in leukaemic stem cells. Leukemia 2005, 19, 381-389.
47. Murnane, J.P. Telomere loss as a mechanism for chromosome instability in human cancer. Cancer Res. 2010, 70, 4255-4259.
48. Hande, M.P. DNA repair factors and telomere-chromosome integrity in mammalian cells. Cytogenet. Genome Res. 2004, 104, 116-122.
49. Gisselsson, D. Mitotic instability in cancer: Is there method in the madness? Cell Cycle 2005, 4, 1007-1010.
50. Briatore, F.; Barrera, G.; Pizzimenti, S.; Toaldo, C.; Casa, C.D.; Laurora, S.; Pettazzoni, P.; Dianzani, M.U.; Ferrero, D. Increase of telomerase activity and hTERT expression in myelodysplastic syndromes. Cancer Biol. Ther. 2009, 8, 883-889.
51. Pettigrew, K.A.; Armstrong, R.N.; Colyer, H.A.; Zhang, S.D.; Rea, I.M.; Jones, R.E.; Baird, D.M.; Mills, K.I. Differential TERT promoter methylation and response to 5-aza-2'- deoxycytidine in acute myeloid leukemia cell lines: TERT expression, telomerase activity, telomere length, and cell death. Genes Chromosomes Cancer 2012, 51, 768-780.
52. Rollison, D.E.; Epling-Burnette, P.K.; Park, J.Y.; Lee, J.H.; Park, H.; Jonathan, K.; Cole, A.L.; Painter, J.S.; Guerrier, M.; Melendez-Santiago, J., et al. Telomere length in myelodysplastic syndromes. Leuk. Lymphoma 2011, 52, 1528-1536.
53. Capraro, V.; Zane, L.; Poncet, D.; Perol, D.; Galia, P.; Preudhomme, C.; Bonnefoy-Berard, N.; Gilson, E.; Thomas, X.; El-Hamri, M., et al. Telomere deregulations possess cytogenetic, phenotype, and prognostic specificities in acute leukemias. Exp. Hematol. 2011, 39, 195-202.e2.
54. Gadji, M.; Adebayo Awe, J.; Rodrigues, P.; Kumar, R.; Houston, D.S.; Klewes, L.; Dieye, T.N.; Rego, E.M.; Passetto, R.F.; de Oliveira, F.M., et al. Profiling three-dimensional nuclear telomeric architecture of myelodysplastic syndromes and acute myeloid leukemia defines patient subgroups. Clin. Cancer Res. 2012, 18, 3293-3304.
55. Calado, R.T.; Young, N.S. Telomere maintenance and human bone marrow failure. Blood 2008, 111, 4446-4455.
56. Young, N.S. Telomere biology and telomere diseases: Implications for practice and research. Hematology Am. Soc. Hematol. Educ. Program 2010, 2010, 30-35.
57. Armanios, M. Syndromes of telomere shortening. Annu. Rev. Genomics Hum. Genet. 2009, 10, 45-61.
58. Kirwan, M.; Vulliamy, T.; Marrone, A.; Walne, A.J.; Beswick, R.; Hillmen, P.; Kelly, R.; Stewart, A.; Bowen, D.; Schonland, S.O., et al. Defining the pathogenic role of telomerase mutations in myelodysplastic syndrome and acute myeloid leukemia. Hum. Mutat. 2009, 30, 1567-1573.
59. Calado, R.T.; Cooper, J.N.; Padilla-Nash, H.M.; Sloand, E.M.; Wu, C.O.; Scheinberg, P.; Ried, T.; Young, N.S. Short telomeres result in chromosomal instability in hematopoietic cells and precede malignant evolution in human aplastic anemia. Leukemia 2012, 26, 700-707.
60. Yamaguchi, H.; Baerlocher, G.M.; Lansdorp, P.M.; Chanock, S.J.; Nunez, O.; Sloand, E.; Young, N.S. Mutations of the human telomerase RNA gene (TERC) in aplastic anemia and myelodysplastic syndrome. Blood 2003, 102, 916-918.
61. Lange, K.; Holm, L.; Vang Nielsen, K.; Hahn, A.; Hofmann, W.; Kreipe, H.; Schlegelberger, B.; Gohring, G. Telomere shortening and chromosomal instability in myelodysplastic syndromes. Genes Chromosomes Cancer 2010, 49, 260-269.
62. Gohring, G.; Lange, K.; Hofmann, W.; Nielsen, K.V.; Hellstrom-Lindberg, E.; Roy, L.; Morgan, M.; Kreipe, H.; Busche, G.; Giagounidis, A., et al. Telomere shortening, clonal evolution and disease progression in myelodysplastic syndrome patients with 5q deletion treated with lenalidomide. Leukemia 2012, 26, 356-358.
63. Sobulo, O.M.; Borrow, J.; Tomek, R.; Reshmi, S.; Harden, A.; Schlegelberger, B.; Housman, D.; Doggett, N.A.; Rowley, J.D.; Zeleznik-Le, N.J. MLL is fused to CBP, a histone acetyltransferase, in therapy-related acute myeloid leukemia with a t(11;16)(q23;p13.3). Proc. Natl. Acad. Sci. USA 1997, 94, 8732-8737.
64. Katsumoto, T.; Yoshida, N.; Kitabayashi, I. Roles of the histone acetyltransferase monocytic leukemia zinc finger protein in normal and malignant hematopoiesis. Cancer Sci. 2008, 99, 1523-1527.
65. Scheuermann, J.C.; de Ayala Alonso, A.G.; Oktaba, K.; Ly-Hartig, N.; McGinty, R.K.; Fraterman, S.; Wilm, M.; Muir, T.W.; Muller, J. Histone H2A deubiquitinase activity of the Polycomb repressive complex PR-DUB. Nature 2010, 465, 243-247.
66. Potapova, A.; Hasemeier, B.; Romermann, D.; Metzig, K.; Gohring, G.; Schlegelberger, B.; Langer, F.; Kreipe, H.; Lehmann, U. Epigenetic inactivation of tumour suppressor gene KLF11 in myelodysplastic syndromes. Eur. J. Haematol. 2010, 84, 298-303.
67. Ono, R.; Taki, T.; Taketani, T.; Taniwaki, M.; Kobayashi, H.; Hayashi, Y. LCX, leukemia- associated protein with a CXXC domain, is fused to MLL in acute myeloid leukemia with trilineage dysplasia having t(10;11)(q22;q23). Cancer Res. 2002, 62, 4075-4080.
68. Koh, K.P.; Yabuuchi, A.; Rao, S.; Huang, Y.; Cunniff, K.; Nardone, J.; Laiho, A.; Tahiliani, M.; Sommer, C.A.; Mostoslavsky, G., et al. Tet1 and Tet2 regulate 5-hydroxymethylcytosine production and cell lineage specification in mouse embryonic stem cells. Cell Stem Cell 2011, 8, 200-213.
69. Matarese, F.; Carrillo-de Santa Pau, E.; Stunnenberg, H.G. 5-hydroxymethylcytosine: A new kid on the epigenetic block? Mol. Syst. Biol. 2011, 7, 562.
70. Figueroa, M.E.; Skrabanek, L.; Li, Y.; Jiemjit, A.; Fandy, T.E.; Paietta, E.; Fernandez, H.; Tallman, M.S.; Greally, J.M.; Carraway, H., et al. MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation. Blood 2009, 114, 3448-3458.
71. del Rey, M.; O'Hagan, K.; Dellett, M.; Aibar, S.; Colyer, H.A.; Alonso, M.E.; Diez-Campelo, M.; Armstrong, R.N.; Sharpe, D.J.; Gutierrez, N.C., et al. Genome-wide profiling of methylation identifies novel targets with aberrant hypermethylation and reduced expression in low-risk myelodysplastic syndromes. Leukemia 2013, 27, 610-618.
72. Shen, Y.; Zhu, Y.M.; Fan, X.; Shi, J.Y.; Wang, Q.R.; Yan, X.J.; Gu, Z.H.; Wang, Y.Y.; Chen, B.; Jiang, C.L., et al. Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia. Blood 2011, 118, 5593-5603.
73. Lugthart, S.; Figueroa, M.E.; Bindels, E.; Skrabanek, L.; Valk, P.J.; Li, Y.; Meyer, S.; Erpelinck-Verschueren, C.; Greally, J.; Lowenberg, B., et al. Aberrant DNA hypermethylation signature in acute myeloid leukemia directed by EVI1. Blood 2011, 117, 234-241.
74. Kustikova, O.S.; Schwarzer, A.; Stahlhut, M.; Brugman, M.H.; Neumann, T.; Yang, M.; Li, Z.; Schambach, A.; Heinz, N.; Gerdes, S., et al. Activation of Evi1 inhibits cell cycle progression and differentiation of hematopoietic progenitor cells. Leukemia 2012, 27, 1127-1138.
75. Lugthart, S.; van Drunen, E.; van Norden, Y.; van Hoven, A.; Erpelinck, C.A.; Valk, P.J.; Beverloo, H.B.; Lowenberg, B.; Delwel, R. High EVI1 levels predict adverse outcome in acute myeloid leukemia: Prevalence of EVI1 overexpression and chromosome 3q26 abnormalities underestimated. Blood 2008, 111, 4329-4337.
76. Li, Z.; Dullmann, J.; Schiedlmeier, B.; Schmidt, M.; von Kalle, C.; Meyer, J.; Forster, M.; Stocking, C.; Wahlers, A.; Frank, O., et al. Murine leukemia induced by retroviral gene marking. Science 2002, 296, 497.
77. Modlich, U.; Schambach, A.; Brugman, M.H.; Wicke, D.C.; Knoess, S.; Li, Z.; Maetzig, T.; Rudolph, C.; Schlegelberger, B.; Baum, C. Leukemia induction after a single retroviral vector insertion in Evi1 or Prdm16. Leukemia 2008, 22, 1519-1528.
78. Karakaya, K.; Herbst, F.; Ball, C.; Glimm, H.; Kramer, A.; Loffler, H. Overexpression of EVI1 interferes with cytokinesis and leads to accumulation of cells with supernumerary centrosomes in G0/1 phase. Cell Cycle 2012, 11, 3492-3503.
79. Vajen, B.; Modlich, U.; Schienke, A.; Wolf, S.; Skawran, B.; Hofmann, W.; Busche, G.; Kreipe, H.; Baum, C.; Santos-Barriopedro, I., et al. Histone methyltransferase Suv39h1 deficiency prevents Myc-induced chromosomal instability in murine myeloid leukemias. Genes Chromosomes Cancer 2013, 52, 423-430.
80. Garcia-Cao, M.; O'Sullivan, R.; Peters, A.H.; Jenuwein, T.; Blasco, M.A. Epigenetic regulation of telomere length in mammalian cells by the Suv39h1 and Suv39h2 histone methyltransferases. Nat. Genet. 2004, 36, 94-99.
81. Louis, S.F.; Vermolen, B.J.; Garini, Y.; Young, I.T.; Guffei, A.; Lichtensztejn, Z.; Kuttler, F.; Chuang, T.C.; Moshir, S.; Mougey, V., et al. c-Myc induces chromosomal rearrangements through telomere and chromosome remodeling in the interphase nucleus. Proc. Natl. Acad. Sci. USA 2005, 102, 9613-9618.
82. Pampalona, J.; Soler, D.; Genesca, A.; Tusell, L. Whole chromosome loss is promoted by telomere dysfunction in primary cells. Genes Chromosomes Cancer 2010, 49, 368-378.
83. Zhong, Z.H.; Jiang, W.Q.; Cesare, A.J.; Neumann, A.A.; Wadhwa, R.; Reddel, R.R. Disruption of telomere maintenance by depletion of the MRE11/RAD50/NBS1 complex in cells that use alternative lengthening of telomeres. J. Biol. Chem. 2007, 282, 29314-29322.
84. Fan, Q.; Zhang, F.; Barrett, B.; Ren, K.; Andreassen, P.R. A role for monoubiquitinated FANCD2 at telomeres in ALT cells. Nucleic Acids Res. 2009, 37, 1740-1754.
85. Karlsson, A.; Deb-Basu, D.; Cherry, A.; Turner, S.; Ford, J.; Felsher, D.W. Defective double-strand DNA break repair and chromosomal translocations by MYC overexpression. Proc. Natl. Acad. Sci. USA 2003, 100, 9974-9979.
86. Ray, S.; Atkuri, K.R.; Deb-Basu, D.; Adler, A.S.; Chang, H.Y.; Herzenberg, L.A.; Felsher, D.W. MYC can induce DNA breaks in vivo and in vitro independent of reactive oxygen species. Cancer Res. 2006, 66, 6598-6605.
87. Smeenk, G.; de Groot, A.J.; Romeijn, R.J.; van Buul, P.P.; Zdzienicka, M.Z.; Mullenders, L.H.; Pastink, A.; Godthelp, B.C. Rad51C is essential for embryonic development and haploinsufficiency causes increased DNA damage sensitivity and genomic instability. Mutat. Res. 2010, 689, 50-58.
88. Fung, T.K.; Siu, W.Y.; Yam, C.H.; Lau, A.; Poon, R.Y. Cyclin F is degraded during G2-M by mechanisms fundamentally different from other cyclins. J. Biol. Chem. 2002, 277, 35140-35149.
89. Ward, I.M.; Minn, K.; van Deursen, J.; Chen, J. p53 binding protein 53BP1 is required for DNA damage responses and tumor suppression in mice. Mol. Cell. Biol. 2003, 23, 2556-2563.
90. Goodarzi, A.A.; Noon, A.T.; Jeggo, P.A. The impact of heterochromatin on DSB repair. Biochem. Soc. Trans. 2009, 37, 569-576.